Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06563765
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
None
First Post:
2024-06-02
Brief Title:
FAP-targeting PETCT for Noninvasive Monitoring of Renal Fibrosis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
FAP-targeting PETCT for Noninvasive Monitoring of Renal Fibrosis
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chronic kidney disease CKD is an irreversible change of kidney function and structure caused by many reasons The main threat of CKD to human health is progressive renal function decline Delaying the progression of chronic kidney disease to end-stage renal failure is an important clinical need and renal fibrosis is a common pathway for the progression of chronic kidney disease to end-stage renal failure The evaluation of renal fibrosis is of great value for the course and prognosis of patients with chronic kidney disease However pathological detection has the disadvantages of trauma false negative and cannot be implemented repeatedly At present there is a lack of effective non-invasive dynamic real-time monitoring and evaluation means A commercially available FAP-targeted imaging agent FAPI-04 has been used for PETCT imaging of systemic fibrosis lesions with high uptake background in normal kidneys Although it can show severe renal fibrosis it is not conducive to the detection rate of patients with mild-moderate fibrosis who need more accurate evaluation The new targeted FAP imaging agent successfully constructed by our research group has proved that it can show the degree of renal fibrosis at the living level and has correlation Therefore this study intends to carry out a series of clinical studies on the imaging of renal fibrosis with new targeted FAP probes evaluate the specificity and sensitivity of the new targeted FAP probes in the diagnosis of renal fibrosis and ultimately provide a new method for clinical dynamic non-invasive assessment and monitoring of the degree and progression of renal fibrosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None